AURA News & Events

The deal size is 39.6M shares of its common stock and in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3.8M shares of common stock. Leerink, TD Cowen and Evercore ISI acted as joint book running managers for the offering.

Aura Biosciences announced that its Board of Directors has appointed Natalie Holles as CEO and President and member of the Board of Directors, effective April 30, 2026. Holles succeeds Elisabet de los Pinos, Ph.D., the company's founder, who stepped down from her roles as CEO and President and member of the Board of Directors on the same date. Prior to joining Aura, Holles served as CEO of Third Harmonic Bio from August 2021 through December 2025. The company also announced that its Phase 3 CoMpass trial with its investigational candidate belzupacap sarotalocan for the treatment of early choroidal melanoma is nearing enrollment completion. Currently, 86 patients have been enrolled in the study, and more than 25 additional patients have been scheduled or identified for screening through May 2026. With this update, the company reiterates its guidance to enrollment completion by mid-2026 and topline data from the CoMpass trial in the second half of 2027.

Aura Biosciences announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Aura. Leerink Partners, TD Cowen and Evercore ISI are acting as joint bookrunning managers for the offering. LifeSci Capital is also acting as a bookrunning manager in the offering. Citizens Capital Markets is acting as a co-manager for the offering.